What happens inside a cell when you switch off a gene or add a compound? Until now, you had to run the experiment to find out.
Venture capital chases clinical results. Government funding is shrinking. A new non-profit called the Thalion Initiative is stepping into the gap with an unusually ambitious fundraising target.
A new AI model can predict how RNA is spliced in different tissues, and can also design new RNA sequences that produce a desired splicing outcome.
A protein best known for helping other proteins fold correctly turns out to play an unexpected role in the cellular response to DNA damage.
A new foundation is offering older patients gene therapy outside of regular clinical channels. The treatments have not been approved by national medicines regulators.
Who is paying for longevity science, and what do they expect in return? At the STAT Breakthrough Summit West, leaders from health care and science gathered for frank conversations.
A longevity startup aiming to add ten healthy years to human lifespan has been valued at 1.8 billion dollars.
An implant that monitors when to release medication and produces that medication itself. Researchers have achieved this using living bacteria enclosed in a material that can be placed inside the body.
Anyone researching longevity supplements runs into the same wall: vast literature, uneven quality, contradictory conclusions. A new open-source system tries to fix that with AI.
An AI system that ‘thinks’ before answering has outperformed human physicians on tasks involving complex reasoning and real-world patient records.
Researchers have designed an improved version of the CRISPR gene-editing tool that can reach more locations in the genome — and they did it entirely through computer simulations, without running a single…
A new breed of AI system that reasons step by step has outperformed experienced physicians on complex clinical cases drawn from real patient data.
Most drug development failures happen not because the biological idea was wrong, but because the molecule had the wrong properties.
Artificial intelligence now scores at the top of medical reasoning tests. The harder question is what that actually means for patients and the future of medicine.
Lung fibrosis replaces healthy tissue with scar tissue, makes breathing progressively harder, and has almost no treatments that reverse the damage.
Drug development for epilepsy has always faced a frustrating bottleneck: waiting for a seizure to happen.
A new type of AI that reasons step by step — rather than just pattern-matching — beat experienced physicians on complex diagnoses using actual clinical records.
From new data on senolytic therapies to AI-designed anti-aging molecules, April 2026 was a busy month for the science of keeping people healthier for longer. Here is what happened.
Life on Earth uses twenty amino acids to build every protein in every living thing. Researchers wondered whether all twenty are truly necessary — and used artificial intelligence to find out.
The cost of testing an experimental treatment in humans has grown so high that many promising longevity interventions never reach the clinic.
A small molecule that blocks one of the body’s central inflammation engines has passed its first clinical test in humans.
Chronic kidney disease affects roughly one in ten adults worldwide, yet the molecular reasons why some patients deteriorate rapidly while others plateau have remained poorly understood.
Antibiotic resistance is one of medicine’s most pressing threats — and one of bacteria’s cleverest tricks is simply pumping drugs back out before they can do any harm.
Proteins are the machines of life — and designing new ones from scratch used to take years of painstaking work. AI has upended that in less than a decade.
Insilico Medicine, a company that uses artificial intelligence to discover new drugs, has signed a deal worth up to $2.75 billion with pharmaceutical giant Eli Lilly.
Proteins are fragile. Heat, acid, mechanical stress — they deform and fall apart. But a new study shows how combining artificial intelligence with classical chemistry can produce a protein scaffold so robust…
BioAge Labs lost its lead drug candidate last year after a phase 2 trial failure. Now the company is reporting positive early-stage data for BGE-102, a new candidate targeting metabolic disease through…
BioAge Labs lost its lead drug candidate last year after a phase 2 trial failure. Now the company is reporting positive early-stage data for BGE-102, a new candidate targeting metabolic disease through…